10.02.14
An advisory committee to the Food and Drug Administration was told that unreasonable FDA restrictions on healthcare use of safe and effective antibacterial ingredients could jeopardize the safety of patients and healthcare workers alike.
In a presentation to FDA’s Nonprescription Drugs Advisory Committee (NDAC) organized by the American Cleaning Institute (ACI), health professionals and industry safety experts said that active ingredients used in antibacterial hygiene products “clearly save lives” and are recognized as the “standard of care” for reducing healthcare infections.
“A robust body of research supports the safety of active ingredients used in healthcare antiseptic products,” wrote ACI in comments submitted to the NDAC panel. “Any suggestion that the benefit or risk of these products is in question, especially by FDA, could lead to unintended adverse consequences if usage patterns were to change in the healthcare setting.”
FDA is slated to propose a new set of rules governing antibacterial healthcare hygiene products in 2015.
Previous public announcements made by FDA, questioning the safety and efficacy of key antibacterial ingredients, have failed to acknowledge the full database of studies and research supporting the ingredients’ benefits and safety profiles.
“Healthcare providers need to have a full range of antibacterial actives at their disposal to best meet their infection control needs,” said ACI associate vice president, environmental safety Dr. Paul DeLeo. “Any effort by FDA that would impede availability of these important ingredients would put patients and healthcare personnel at risk.”
In a presentation to FDA’s Nonprescription Drugs Advisory Committee (NDAC) organized by the American Cleaning Institute (ACI), health professionals and industry safety experts said that active ingredients used in antibacterial hygiene products “clearly save lives” and are recognized as the “standard of care” for reducing healthcare infections.
“A robust body of research supports the safety of active ingredients used in healthcare antiseptic products,” wrote ACI in comments submitted to the NDAC panel. “Any suggestion that the benefit or risk of these products is in question, especially by FDA, could lead to unintended adverse consequences if usage patterns were to change in the healthcare setting.”
FDA is slated to propose a new set of rules governing antibacterial healthcare hygiene products in 2015.
Previous public announcements made by FDA, questioning the safety and efficacy of key antibacterial ingredients, have failed to acknowledge the full database of studies and research supporting the ingredients’ benefits and safety profiles.
“Healthcare providers need to have a full range of antibacterial actives at their disposal to best meet their infection control needs,” said ACI associate vice president, environmental safety Dr. Paul DeLeo. “Any effort by FDA that would impede availability of these important ingredients would put patients and healthcare personnel at risk.”